Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
granulocyte colony-stimulating factor + interleukin-11
- Development stage
- Unknown
- Lead developer
- Fudan University
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
granulocyte colony-stimulating factor + interleukin-11 is a combination therapy comprising two recombinant human cytokines: rhG-CSF and rhIL-11. G-CSF is a hematopoietic growth factor that stimulates the bone marrow to produce and release neutrophils into the bloodstream. Interleukin-11 is a pleiotropic cytokine that stimulates megakaryocytopoiesis, leading to the production of platelets. This combination is being investigated by Fudan University as a mobilization regimen to improve hematopoietic reconstitution, specifically targeting megakaryocytic and erythroid lineages, in patients with multiple myeloma or lymphoma undergoing autologous hematopoietic stem cell transplantation (auto-HSCT). Preclinical and early clinical data suggest that the combination significantly increases the yield of functional progenitor cells and shortens the time to platelet engraftment compared to G-CSF alone.
- Brand names
- NeumegaNeupogen
- Other names
- G-CSF + IL-11rhG-CSF + rhIL-11G-CSF + Interleukin-11
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)IL11RA (Interleukin-11 receptor subunit alpha)
Beyond the preview
Go deeper on granulocyte colony-stimulating factor + interleukin-11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on granulocyte colony-stimulating factor + interleukin-11.